109 related articles for article (PubMed ID: 9470851)
1. Experimental antitumour activity of S 16020-2 in a panel of human tumours.
Kraus-Berthier L; Guilbaud N; Jan M; Saint-Dizier D; Rouillon MH; Burbridge MF; Pierré A; Atassi G
Eur J Cancer; 1997 Oct; 33(11):1881-7. PubMed ID: 9470851
[TBL] [Abstract][Full Text] [Related]
2. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts.
Hill BT; Fiebig HH; Waud WR; Poupon MF; Colpaert F; Kruczynski A
Eur J Cancer; 1999 Mar; 35(3):512-20. PubMed ID: 10448309
[TBL] [Abstract][Full Text] [Related]
3. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of treatment of colon, lung and breast human carcinoma xenografts with: doxorubicin, cisplatin, irinotecan or topotecan.
Hardman WE; Moyer MP; Cameron IL
Anticancer Res; 1999; 19(3B):2269-74. PubMed ID: 10472342
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of S 16020-2 in two orthotopic models of lung cancer.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Pierré A; Atassi G
Anticancer Drugs; 1997 Mar; 8(3):276-82. PubMed ID: 9095333
[TBL] [Abstract][Full Text] [Related]
7. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
Van Hattum AH; Pinedo HM; Schlüper HM; Hausheer FH; Boven E
Int J Cancer; 2000 Oct; 88(2):260-6. PubMed ID: 11004678
[TBL] [Abstract][Full Text] [Related]
8. The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts.
Breistøl K; Hendriks HR; Berger DP; Langdon SP; Fiebig HH; Fodstad O
Eur J Cancer; 1998 Sep; 34(10):1602-6. PubMed ID: 9893636
[TBL] [Abstract][Full Text] [Related]
9. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
[TBL] [Abstract][Full Text] [Related]
10. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
[TBL] [Abstract][Full Text] [Related]
11. Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity.
Burbridge MF; Kraus-Berthier L; Naze M; Pierre A; Atassi G; Guilbaud N
Int J Oncol; 1999 Dec; 15(6):1155-62. PubMed ID: 10568822
[TBL] [Abstract][Full Text] [Related]
12. Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites.
Boven E; de Jong J; Kuiper CM; Bast A; van der Vijgh WJ
Eur J Cancer; 1996 Jul; 32A(8):1382-7. PubMed ID: 8869103
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor efficacy of paclitaxel against human lung cancer xenografts.
Yamori T; Sato S; Chikazawa H; Kadota T
Jpn J Cancer Res; 1997 Dec; 88(12):1205-10. PubMed ID: 9473739
[TBL] [Abstract][Full Text] [Related]
14. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic response of human tumor xenografts in athymic mice to doxorubicin.
Giuliani FC; Zirvi KA; Kaplan NO
Cancer Res; 1981 Jan; 41(1):325-35. PubMed ID: 7448772
[TBL] [Abstract][Full Text] [Related]
16. Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere).
Dykes DJ; Bissery MC; Harrison SD; Waud WR
Invest New Drugs; 1995; 13(1):1-11. PubMed ID: 7499102
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
Geiger T; Müller M; Monia BP; Fabbro D
Clin Cancer Res; 1997 Jul; 3(7):1179-85. PubMed ID: 9815797
[TBL] [Abstract][Full Text] [Related]
18. FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice.
Naoe Y; Inami M; Matsumoto S; Takagaki S; Fujiwara T; Yamazaki S; Kawamura I; Nishigaki F; Tsujimoto S; Manda T; Shimomura K
Jpn J Cancer Res; 1998 Dec; 89(12):1306-17. PubMed ID: 10081492
[TBL] [Abstract][Full Text] [Related]
19. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice.
Kumazawa E; Jimbo T; Ochi Y; Tohgo A
Cancer Chemother Pharmacol; 1998; 42(3):210-20. PubMed ID: 9685056
[TBL] [Abstract][Full Text] [Related]
20. Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent.
Hendriks HR; Plowman J; Berger DP; Paull KD; Fiebig HH; Fodstad O; Dreef-van der Meulen HC; Henrar RE; Pinedo HM; Schwartsmann G
Ann Oncol; 1992 Nov; 3(9):755-63. PubMed ID: 1450065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
